Latest recommendation updates
ATAGI Clinical Guidance and other provider resources have been updated with information on additional winter booster doses.
ATAGI have published advice on the use of sedation for COVID-19 vaccination which provides a broad overview of the principles for the use of sedation as one of a range of measures to assist in the safe administration of COVID-19 vaccines.
Recent ATAGI considerations
On Wednesday 30 March 2022, ATAGI met to consider the latest developments relating to COVID-19 immunisation. As of 29 March 2022, over 56 million doses of COVID-19 vaccines have been administered in Australia.
ATAGI encourages parents of children aged 5-11 to make an appointment for the second dose of COVID-19 vaccine.
ATAGI encourages anyone aged 16 years and over to receive a booster dose as soon as they are eligible. More information on COVID-19 boosters.
Ongoing ATAGI considerations
ATAGI is continuing to review all available and emerging evidence on the use of COVID-19 vaccines and treatments as part of its ongoing review of current recommendations.
ATAGI is also continuing to review evidence on the use of COVID-19 booster doses in adolescents aged 12-15 years, including data on serious illness, epidemiology and international use in this age group, including use in those with immuno-compromising conditions.
COVID-19 vaccine safety
The TGA Weekly Report provides a detailed breakdown of adverse events following immunisation.
Resources and recent statements
ATAGI recommends review of the following key resources:
- 6 April 2022: ATAGI advice on use of sedation for COVID-19 vaccination
- 25 March 2022: ATAGI recommendations on a winter booster dose of COVID-19 vaccine
- 2 March 2022: ATAGI updated advice on COVID-19 booster vaccinations
- 28 February 2022: ATAGI Clinical Guidance for COVID-19 vaccine providers
- 18 February 2022: ATAGI guidance on temporary medical exemptions for COVID‑19 vaccines
- 3 February 2022: ATAGI Statement on booster doses for adolescents aged 16 to 17 years
- 24 January 2022: ATAGI statement on the use of Novavax COVID-19 vaccine
- 19 January 2022: Updated ATAGI recommendations on the use of a third primary dose of COVID-19 vaccine in individuals who are severely immunocompromised.
More information can be found on the Department of Health website, with resources for both providers and patients.